{"url_path":"/sec/nrxp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-017397-index.html","accession_number":"0001437749-26-017397","cik":"0001719406","ticker":"NRXP","issuer_name":"NRX Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-017397-index.html","primary_entity_key":"0001719406","primary_entity_name":"NRX Pharmaceuticals, Inc."},"word_count":65,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\nNone of our directors or executive officers adopted or terminated a Rule *10b5*-*1* trading arrangement or a non-Rule *10b5*-*1* trading arrangement during the quarter ended *March 31, 2026,*as such terms are defined under Item *408*(a) of Regulation S-K. Additionally, we did *not* adopt or terminate a Rule *10b5*-*1* trading arrangement during the quarter ended *March 31, 2026.*\n\n  \n\n49\n\n[Table of Contents](#toc)"}